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ABSTRACT
Background Anti-programmed cell death protein 1 and
programmed cell death ligand 1 (PD-L1) agents are broadly
used in first-line and second-line treatment across different
tumor types. While immunohistochemistry-based assays are
routinely used to assess PD-L1 expression, their clinical utility
remains controversial due to the partial predictive value and
lack of standardized cut-offs across antibody clones. Using
a high throughput immunoassay, the reverse phase protein
microarray (RPPA), coupled with a fluorescence-based
detection system, this study compared the performance of
six anti-PD-L1 antibody clones on 666 tumor samples.
Methods PD-L1 expression was measured using five
antibody clones (22C3, 28–8, CAL10, E1L3N and SP142)
and the therapeutic antibody atezolizumab on 222 lung,
71 ovarian, 52 prostate and 267 breast cancers, and 54
metastatic lesions. To capture clinically relevant variables,
our cohort included frozen and formalin-fixed paraffin-
embedded samples, surgical specimens and core needle
biopsies. Pure tumor epithelia were isolated using laser
capture microdissection from 602 samples. Correlation
coefficients were calculated to assess concordance
between antibody clones. For two independent cohorts of
patients with lung cancer treated with nivolumab, RPPA-
based PD-L1 measurements were examined along with
response to treatment.
Results Median-center PD-L1 dynamic ranged from 0.01
to 39.37 across antibody clones. Correlation coefficients
between the six antibody clones were heterogeneous
(range: −0.48 to 0.95) and below 0.50 in 61% of the
comparisons. In nivolumab-treated patients, RPPA-based
measurement identified a subgroup of tumors, where low
PD-L1 expression equated to lack of response.
Conclusions Continuous RPPA-based measurements
capture a broad dynamic range of PD-L1 expression
in human specimens and heterogeneous concordance
levels between antibody clones. This high throughput
immunoassay can potentially identify subgroups of tumors
in which low expression of PD-L1 equates to lack of
response to treatment.

BACKGROUND
Therapeutic agents targeting the programmed
cell death protein 1 (PD-1) and programmed
cell death ligand 1 (PD-
L1) significantly
increase survival in patients with cancer and
are broadly used as first-line and second-line
treatments across different types of solid
tumors.1–3 However, the search for robust and
reliable biomarkers able to predict outcome
to these targeted compounds remains an
open challenge in immuno-oncology.4 5
Tumor mutational burden has been
recently approved by the Food and Drug
Administration (FDA) as a predictive marker
of response to pembrolizumab in unresectable or metastatic solid tumors, however its
broad use still remains challenging from a
technical perspective.6 Immunohistochemistry (IHC)-based assays, on the other hand,
are widely used as gold-standard for assessing
biomarker expression in oncology, including
the FDA-approved and European Conformity-
Mark certified companion/complementary
tests for PD-L1 quantification and treatment
stratification. However, the utility of these
assays as companion/complementary tests
in immuno-oncology remains controversial,
despite their systemic use, due to their partial
predictive value and lack of standardized cut-
offs across antibody clones which make these
assays poorly interchangeable and prone to
samples’ misclassification.7–10
IHC-
based measurements are semi-
quantitative, subjective by nature, and highly
dependent on antigen retrieval protocols. In
addition, the colorimetric detection used in
IHC-
based analysis renders these platforms
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METHODS
Sample collection
To explore PD-L1 expression by RPPA on clinically relevant samples, we used 10 independent study sets including
666 cancer tissues (figure 1A). Sets 1–5 were collected
from patients with lung cancer and included snap-frozen
and formalin-fixed paraffin-embedded (FFPE) samples
as well as surgical specimens and core needle biopsies.
Clinical–pathological characteristics of the five cohorts
of patients are presented in table 1. Sets 1 and 2 were
collected at the Santa Maria della Misericordia Hospital
(Perugia, Italy) and included 33 whole tissue lysates and
58 microdissected surgical specimens, respectively.22
Matched dissected (2E) and undissected (2W) samples
were collected for a subset of biospecimens included in
study Set 2 for a final sample size of 73 samples. Set 3
frozen Non-
Small Cell Lung Cancer
included 45 snap-
(NSCLC) cancers surgical specimens collected at University of Padova (Italy).23
Set 4 included pretreatment FFPE surgical specimens
and core needle biopsies collected from 32 patients
with lung cancer undergoing immunotherapy for which
retrospective material was available for molecular analysis. Biospecimens were collected at diagnosis or during
follow-up visits between 2010 and 2016 by the Lombardi
Comprehensive Cancer Center at Georgetown University and the Santa Maria della Misericordia Hospital
(Perugia, Italy). Matched dissected and undissected
samples were available for 16 of the 32 samples. Of the 32
patients included in this analysis, 28 patients were treated
with nivolumab. This group of patients was included in
a subanalysis assessing the association between PD-
L1
measurement by RPPA and patients’ responses to treatment. Set 5 included 23 pretreatment FFPE surgical specimens and core needle biopsies collected from patients
with NSCLC undergoing immunotherapy. Samples were
collected at the Santa Maria della Misericordia Hospital
(Perugia, Italy) between 2008 and 2015. Patients were

Figure 1 Main characteristics of the 10 study sets included in the analysis. A total of 666 samples were used to capture
clinically relevant preanalytical variables including anatomical origin of the tumor, sample collection methods, specimen type,
and cellular compartment in which programmed cell death ligand 1 (PD-L1) expression was evaluated (A). Anti-PD-L1 antibody
clones used for each study set (B). E, dissected; FFPE, formalin-fixed paraffin-embedded; W, undissected.

2

Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

J Immunother Cancer: first published as 10.1136/jitc-2020-002179 on 7 October 2021. Downloaded from http://jitc.bmj.com/ on October 25, 2021 by guest. Protected by copyright.

inadequate to fully capture linear relationships between
expression of predictive biomarkers and outcome. Thus,
the utility of the IHC may be limited as it mostly captures
large scale differences across clinical samples and additional testing is usually required to correctly classify equivocal measurements.11 Quantitative assays able to provide
continuous output data represent a powerful alternative
from a diagnostic perspective. A recent study exploring
PD-
L1 expression in lung cancers using parallel reaction monitoring-based mass spectrometry (MS) showed
a wide dynamic range of PD-
L1 expression across
samples.12 However, concordance in PD-
L1 expression
between continuous MS data and qualitative IHC-based
measurements was weak and the broad dynamic range
was only partially captured by the IHC platform.12 For a
therapeutic perspective, quantitative human epidermal
growth factor receptor 2 (HER2) measurements in breast
cancer specimens have shown superior performance in
predicting response to targeted therapies compared with
IHC-based, semi-quantitative measurements.13–16 The
wider dynamic range captured by these quantitative platforms has been addressed as a key element for increasing
precision and for accurately distinguishing responders
from non-responders, especially from IHC-negative specimens.15 17
In this study we tested the feasibility of using reverse
phase protein microarray (RPPA), a non-subjective, quantitative, and calibrated immunoassay currently used in
precision medicine clinical trials,18–21 to capture PD-L1
expression on cancer cells and predict response to anti-
PD-
1/PD-
L1 compounds. PD-
L1 expression was quantified on 64 undissected and 602 microdissected tumor
epithelia with six antibody clones, including two antibodies routinely used in FDA-cleared assays (Dako 22C3
and Ventana SP142) and the therapeutic anti-PD-L1 antibody atezolizumab. Lastly, continuous PD-L1 measurements were explored along with patients’ outcomes to
assess the ability of the RPPA platform to identify patients
that may benefit from treatment.
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Patient demographics

Set 1

Set 222

Set 323

Set 4

Set 5

Number of samples
 Age (average and range)

33
71 (51–90)

58
69 (48–90)

47
66 (48–85)

32
66 (37–86)

23
66 (49–80)*

 Male

12 (36.4)

29 (50)

36 (76.6)

15 (46.9)

19 (82.6)

 Female

21 (63.6)

29 (50)

11 (23.4)

17 (53.1)

4 (17.4)

Sex N (%)

Histology N (%)
 Adenocarcinoma

32 (97)

58 (100)

27 (57.4)

15 (46.9)

17 (74)

 Squamous carcinomas

–

–

20 (42.6)

8 (25)

6 (26)

 Carcinomas NOS

–

–

–

6 (18.8)

 Carcinomas with neuroendocrine features
 Unknown

1 (3)
–

–

–

–

2 (6.3)

–

–

–

1 (3)

–

34 (58.6)

–

–

6 (26.1)

11 (19)

–

–

3 (13)

Stage
 I

7 (21.2)

 II

16 (48.5)

 III

3 (9.1)

12 (20.7)

–

–

 IV

7 (21.2)

1 (1.7)

–

32 (100)

 Mutant

18 (54.5)

34 (58.6)

–

–

 Wild-type
 Unknown

15 (45.5)
–

24 (41.4)
–

–
47 (100)

–
32 (100)

3 (13)
11 (47.9)

KRAS status
4 (17.4)
15 (65.2)
4 (17.4)

* age is missing for two patients.
KRAS, Kirsten rat sarcoma viral oncogene homolog; NOS, Not otherwise specified; NSCLC, Non-Small Cell Lung Cancer.

treated with nivolumab and response rates for Sets 4 and
5 were assessed using the Response Evaluation Criteria in
Solid Tumors (RECIST) V.1.1 criteria.24 Sets 6–10 were
used to examine the relationship between anti-PD-L1 antibody clones in different tumor types. Set 6 included 71
snap-frozen samples collected from patients with chemo-
naïve ovarian cancer treated at the Division of Gynecology
Oncology, University of Brescia (Brescia, Italy).25 Set 7
comprised 52 snap-frozen biopsies collected from patients
with prostate cancer treated at the Institute of Cancer
Research (UK). Sets 8 and 9 included biospecimens
collected through two clinical trials targeting patients
with primary and metastatic breast cancer (NCT01042379
and NCT03195192). Specifically, Set 8 included 243 snap-
frozen pretreatment core needle biopsies collected from
patients enrolled in the I-
SPY 2 TRIAL,26 while Set 9
included 24 FFPE pretreatment samples collected for the
Side Out 3 metastatic breast clinical trial.27 Finally, Set 10
included 54 snap-frozen surgical specimens from brain
metastases of breast (n=10) and lung (n=32) cancers, and
from tumors of other origin (n=12).28
Western blotting
The ability of the six antibodies to capture PD-
L1 in
denatured conditions was first tested by western blotting following standard protocols.29 Each membrane was
probed with one anti-PD-L1 antibody (22C3 M3653/Dako;
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

28–8 ab205921/Abcam; E1L3N 13 684/Cell Signaling
Technology; SP142 740–4859/Roche; and atezolizumab
A2004/Selleckchem) at 4°C overnight. Membranes were
washed and subsequently incubated with a 1:10 000 dilution of horseradish peroxidase-conjugated (HRP) anti-
mouse (Invitrogen, Carlsbad, California) or anti-rabbit
(Invitrogen) antibody. Atezolizumab was directly biotinylated using a commercially available kit (Lightning Link
Rapid Biotin Type A, Expedeon, Heidelberg, Germany)
per manufacturer’s recommendations and incubated
with streptavidin HRP (Invitrogen) at a 1:15 000 dilution. Blots were washed and developed using a chemiluminescence HRP substrate-based system (SuperSignal
West Dura, Thermo Fisher, Waltham, Massachusetts)
according to the manufacturer’s protocols. Images were
acquired using the Eastman Kodak 4000 MM Image
Station (Kodak, Rochester, New York).
Laser microdissection
For Sets 1, 2W and 4W, whole tissues were directly lysed
from 8 µm cryosections. Snap-
frozen and FFPE tissues
of Sets 2E–10 were subjected to laser microdissection.
We have previously demonstrated that the laser capture
microdissection (LCM) protocol described below does
not affect protein expression or activation.30 For Set 4,
when possible, two cellular compartments were microdissected: the tumor epithelium and the tumor stroma
3
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Table 1 Clinical pathological characteristics of patients with NSCLC included in Sets 1–5
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Protein extraction
Frozen samples were lysed in a 1:1 solution of Tissue
Protein Extraction Reagent (Pierce, Rockford, Illinois,
USA) and 2X Tris-Glycine SDS Sample buffer (Invitrogen
Life Technologies, Carlsbad, California) supplemented
with 2.5% of 2 β-mercaptoethanol (Sigma Aldrich). Cell
lysates were boiled for 8 min and stored at −80°C. FFPE
samples were lysed using the QProteome kit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions. Briefly, polymers were removed from the CapSure
Macro LCM Caps and collected into an individual screw
top tube. Qiagen Extraction Buffer EXB Plus supplemented with 6% β-mercaptoethanol was added to each
screw top tube (1 µl of buffer per ~250 cells captured).
Samples were incubated at 4°C for 5 min, boiled for 20 min
in a heating block, and subsequently placed in 80°C water
bath for 2 hours. Afterward, samples were placed on ice
for 1 min and centrifuged at 14 000×g for 15 min at 4°C.
Supernatants were collected and stored at −80°C.
Reverse phase protein microarray
Using the 2470 Aushon Arrayer (Quanterix, Billerica,
Massachusetts) equipped with 185 µm pins, samples were
immobilized onto nitrocellulose-coated glass slides (Grace
Biolabs, Bend, Oregon) in technical replicates (n=3)
along with a reference standard, and internal controls as
previously described.32 Standard curves were prepared
using commercially available cell lysates with high and
low PD-L1 expression previously identified by RPPA and
printed on selected arrays. SUPM2 and UV treated NIH
3T3 cells were identified as PD-L1 expressing cells and
Untreated HeLa were used as control. All three cell lines
were diluted to a final concentration of 0.25 µg/µl. A
six-point standard curve was created by mixing different
amounts of the high and low expressing line to progressively decrease PD-
L1 expression while maintaining a
4

constant protein concentration across each point of the
standard curve.33
A four-
point bovine serum albumin serial dilution
curve was printed along with the experimental samples to
estimate protein amounts in each sample with a starting
concentration of 1 µg/µl. Protein concentration was
assessed using a Sypro Ruby Protein Blot Stain (Molecular Probes, Eugene, Oregon), according to the manufacturer’s instruction. In brief, arrays were fixed for 15 min
in a 7% acetic acid and 10% methanol staining solution
followed by four 5 min washes in deionized water and
incubated with Sypro Ruby Protein Blot Stain for 30 min.
Before immunostaining, remaining slides were
treated with Reblot Plus Mild Antibody stripping solution (MilliporeSigma, Burlington, Massachusetts) for
15 min at room temperature, washed twice with PBS,
and incubated in I-block solution (Applied Biosystems)
for at least 4 hours. Immunostaining was performed on
an automated system (Dako Cytomation, Carpinteria,
California) where each array was probed with one antibody targeting a protein of interest. PD-L1 expression
was measured with five antibody clones, including:
22C3 (1:50; mouse; M3653; Dako); 28–8 (1:500; rabbit;
ab205921; Abcam); CAL10 (1:200; rabbit; AC13171A;
Biocare); E1L3N (1:500; rabbit; 13684; Cell Signaling
Technology) and SP142 (1:50; rabbit; 740–4859; Roche).
Atezolizumab, the humanized monoclonal antibody used
as a therapeutic agent targeting PD-L1, was also used as
primary antibody (1:100; Human; A2004; Selleckchem).
Samples were then probed with a biotinylated goat anti-
rabbit (Vector Laboratories; 1:7500), rabbit anti-mouse
(Dako; 1:10), or anti-
human (Vector Laboratories;
1:7500) secondary antibodies matching the species of
the primary antibody. Signal detection was performed
using a commercially available tyramide-based Catalyzed
Signal Amplification System (CSA, Dako) coupled with
a fluorescent streptavidin-
conjugated IRDye680 dye
(LI-
COR Biosciences, Lincoln, Nebraska).32 For each
staining batch, one slide was probed with the secondary
antibody only and used as negative control for normalization purposes. As a control to capture concordance
between antibody clones by RPPA, three study Sets were
also stained with two antibodies targeting phosphorylated
S6 Ribosomal Protein (S6 Ribosomal Protein S235/236;
1:200; rabbit; 4856; Cell Signaling Technology and S6
Ribosomal Protein S240/244; 1:1000; rabbit; 2215; Cell
Signaling Technology), two targeting phosphorylated
AKT (AKT S473; 1:100; rabbit; 9271; Cell Signaling Technology, and AKT T308; 1:100; rabbit; 9275; Cell Signaling
Technology) and two humanized antibodies targeting
PD-
1 (pembrolizumab; 1:100; human; A2005; Selleckchem, and nivolumab; 1:100; human; A2002; Selleckchem). To estimate immune infiltrate, the TSI was also
stained with an anti-CD45 antibody (1:200; mouse; BD).
Antibody and Sypro Ruby Protein Blot stained arrays
were scanned with a laser PowerScanner (TECAN,
Männedorf, Switzerland) using the appropriate wavelength channel.32 Image analysis was performed using a
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179
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interface (TSI), a non-cancerous area within 30 µm from
tumor compartment margin (online supplemental figure
S1). For all 10 Sets, tissues were cut into 8 µm sections and
mounted onto uncharged glass slides. One Hematoxylin
(Sigma Aldrich, St. Louis, Missouri) and Eosin (Sigma
Aldrich) stained slide was prepared for each sample and
used for histopathological evaluation. Staining protocol
has been previously described.31 For Sets 4, 5 and 9
FFPE sections were first deparaffinized in xylene (Sigma
Aldrich) for 30 min and hydrated in serial dilutions of
ethanol (100%, 95% and 70%) (Sigma Aldrich) immediately before dissection. Frozen sections of the remaining
study Sets were hydrated in 70% ethanol. All sections
were then rinsed in deionized water, washed in Scotts’
tap water (Electron Microscopy Sciences, Hatfield, Pennsylvania), dehydrated in ethanol (70%, 95% and 100%)
and xylene, and quickly dried at room temperature. From
each tissue section, the tumor epithelium was collected
on CapSure Macro LCM Caps (Applied Biosystems,
Foster City, California).

Open access

Immunohistochemistry
For a subset of samples in Set 4 and for Set 5, IHC-based
PD-L1 expression data were collected by the pathology
departments of the enrolling institutions following standard protocols. IHC data were collected using the FDA-
approved 22C3 pharmDx assay for 15 of the 32 samples
and with the E1L3N clone for Set 5. IHC for clone E1L3N
was performed using a laboratory developed test on FFPE
archival tissues using the BOND-III fully automated IHC
stainer (Leica Biosystems, Wetzlar, Germany). Antigen
retrieval was performed using citrate buffer at pH=9 for
20 min, followed by incubation with primary antibody
(1:200; rabbit; 13684; Cell Signaling Technology) for
15 min.35
Statistical analysis
RPPA continuous data were used to assess the concordance between anti-PD-L1 antibody clones within each
study Set. Given the exploratory nature of this work, to
assess the ability of the RPPA platform to predict response
to nivolumab, we defined low PD-L1 expressing tumors as
those belonging to the bottom tertial of the population in
Sets 4E and 5. At large, this arbitrary cut-off value seemed
to correspond with an inflection point in our sample
distribution for both Sets 4E and 5. Spearman rank-order
correlation coefficients (rs), coefficient of determination
(R2), linear regression plots, and scatterplot matrixes
were calculated and/or displayed using JMP V.5.1 (SAS
Institute). Median-
centered dynamic range was calculated as follows. For each population, the median value
was first calculated and all samples were then normalized to the corresponding median value. Dynamic ranges
were displayed using Tableau V.2020.1 (Tableau Software,
Seattle, Washington). Non-parametric mean comparisons
were performed in SPSS V.26. Images were modified in
Photoshop V.11 (Adobe) for publication purposes.

RESULTS
Quantitative PD-L1 measurements by RPPA on whole tissues
and enriched tumor epithelia across tumor types
Given the high analytical concordance reported in the
literature, but poor cut-
point reproducibility across
clones resulting in misclassification of PD-L1 status for
some specimens,7 9 10 we first explored concordance
between five diagnostic and one therapeutic anti-PD-L1
antibody clones in ten independent study Sets. A total of
666 samples were used to capture a broad range of preanalytical and clinical variables including sample collection
methods (snap-frozen vs FFPE), type of input material
(surgical specimens vs core needle biopsies), anatomical
origin of the tumor, primary or metastatic lesions, and
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

PD-L1 staining on tumor cells and surrounding microenvironment (whole tissues and pure tumor epithelia)
(figure 1A). Our analysis included two antibodies developed for FDA-
cleared assays (Dako 22C3 and Roche
SP142),11 three antibodies used in laboratory-based assays
(Abcam 28–8, Cell Signaling E1L3N, Biosource CAL10),
and one humanized antibody approved by the FDA as a
therapeutic agent (atezolizumab) (figure 1B). The Abcam
28–8 clone targets the same epitope as the antibody
included in the FDA approved IHC-based 28–8 pharmDx
assay from Agilent. Five of the six antibodies were first
tested using western blotting to confirm their ability to
recognize epitopes in denatured lysates and assess their
specificity. Bands were detected at the predicted molecular weight exclusively as previously described (online
supplemental figure S2A,B).36 37 Affinity for the four
cell lines varied from antibody to antibody. Similarly, the
linear and dynamic range for each of the five diagnostic/
laboratory-
developed clones against a reference standard prepared with a combination of cell lines with high
and low PD-L1 expression varied greatly across antibody
clones (online supplemental figure S3).38
Median-centered RPPA-based PD-L1 continuous data
showed dynamic ranges between 0.01 and 39.37 across
the 10 study Sets analyzed (online supplemental figure
S4,5). Broader distributions were detected for the CAL10
and E1L3N, with the exception of Set 6 and Set 8 where
the largest dynamic range was detected for the SP142
clone. Atezolizumab had the most compressed dynamic
range in 7 of the 10 (67%) study sets. As expected,
when dissected and matched undissected samples were
compared, enriched epithelial samples had a broader
dynamic range regardless of the sample collection
method (Set 2 and Set 4 online supplemental figure S4).
Pairwise comparisons between the six anti-
PD-
L1 antibodies showed a high level of heterogeneity, with overall
low-to-moderate concordance, across the 10 study Sets.
Positive correlation coefficients ranged between 0.006
and 0.95 and negative coefficients between −0.03 and
−0.48 (figure 2A–G, online supplemental figure S6 and
table 1). The highest levels of concordance were detected
between atezolizumab and the 28–8 clone in lung cancer
samples where 4 of the 7 Sets had rs≥0.75 (Set 1, Set 2E,
Set 4E and 4W). Correlation coefficients >0.62 were also
detected in Sets 7, 8, and 9. Generally strong correlations
(rs≥0.70) were also detected between CAL10 and SP142,
CAL10 and E1L3N, and E1L3N and SP142 in 6 of the 9
(66.7%) study Sets (figure 2, online supplemental figure
S6 and table S1). As expected, higher levels of concordance were detected in the enriched tumor epithelial
samples compared with the matched whole tissue lysates
(figure 2, and online supplemental figure S7).
We then compared concordance between three antibodies routinely used in FDA-cleared assays for patients’
stratification to nivolumab (Abcam 28-
8), pembrolizumab (Dako 22C3), and atezolizumab (Roche SP142).
As expected, SP142 showed overall low level of concordance with both the 28–8 and the 22C3 clones (figure 2,
5
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commercially available software (MicroVigene V.5.1.0.0,
VigeneTech).34 The software automatically performs
spot finding and subtraction of local background and
unspecific signal. Samples were then normalized to the
amount of protein and averaged across replicates.

Open access

online supplemental figure S6 and table S1). Regression
analysis for SP142 and 28–8 clones showed R2 ranged
between 0.01 and 0.37 with the exception of Sets 4E and
4W (R2 >0.51) (figure 2, online supplemental figure
S6). Similarly, R2 between the SP142 and the 22C3 clone
were between 0.001 and 0.26 with the exception of Set
5 (R2 >0.70) (figure 2, online supplemental figure S6).
On the contrary, concordance between the SP142 and
E1L3N clones reached R2 between 0.79 and 0.92 for five
of the analyzed sets. Finally, we explored concordance
between the 22C3 and the 28–8 clones across all study
Sets. R2 ranged between 0.005 and 0.18 and only Set 5
had R2 >0.40 (figure 2, online supplemental figure S6).
Overall these data indicate poor concordance between
these three diagnostic clones regardless of tumor types,
sample collection methods, and primary and metastatic
lesions (figure 2A-G, online supplemental figure S6 and
table S1).
Finally, although we did not directly isolate immune
cells from our samples, for a subset of samples included
in Set 4 (n=26), we collected non-malignant cells in near
6

proximity to the tumor cells; we called this compartment
TSI. The TSI was specifically defined as the area within
a 30 µm distance from the tumor compartment (online
supplemental figure S1). We captured PD-L1 expression
within this compartment with the six anti-PD-L1 antibody
clones previously described. In addition, to assess immune
infiltrate in the TSI, we stained the samples with an anti-
CD45 antibody. We then looked at correlation levels
between the different antibody clones in all 26 samples
as well as in samples with high CD45 (above population
median) and low CD45 (below the population median),
respectively. Coefficients of determination across all
samples were similar to the one detected in the tumor
compartment. When samples were subclassified based on
the high or low CD45 expression, coefficients of determination across antibody clones were higher in samples with
a greater number of immune cells (figure 3).
Because correlative levels between anti-
PD-
L1 antibodies were lower than expected, as a control experiment,
we explored concordance between antibodies targeting
different activation sites of the S6 Ribosomal Protein
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179
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Figure 2 Correlation matrixes using Spearman’s Rho correlation coefficients along with matching regression plots across
anti-PD-L1 antibody clones. Levels of concordance between six anti-PD-L1 antibodies vary within the the five Non-Small
Cell Lung Cancer (NSCLC) Sets. Regression plots illustrate level of concordance between antibodies used in Food and Drug
Administration-cleared assays along with the research only anti-PD-L1 antibody E1L3N. E, dissected cancer epithelia; PD-L1,
programmed cell death ligand 1; RPPA, reverse phase protein microarray; R2, coefficient of determination; W, undissected
whole tissue lysates.
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Figure 3 Correlation matrixes displaying Spearman’s Rho correlation coefficients along with matching regression plots
across anti-PD-L1 antibody clones in the tumor-stroma interface. Levels of concordance between six anti-PD-L1 antibodies
in the tumor stroma interface of samples included in Set 4 are shown across all samples (A) and in samples with high CD45
(B) and low CD45 expression (C). Regression plots illustrate levels of concordance between antibodies used in Food and Drug
Administration-cleared assays along with the research only anti-PD-L1 antibody E1L3N. PD-L1, programmed cell death ligand
1; RPPA, reverse phase protein microarray; R2, coefficient of determination.
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179
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Quantitative PD-L1 measurements as predictor of response in
patients with lung cancer treated with nivolumab
Given the heterogeneous and highly dynamic range of
PD-L1 expression captured by RPPA, continuous PD-L1
measurements were explored along with patients’
outcomes to assess the ability of the platform to identify
patients that may benefit from treatment. For this analysis we used 28 samples included in Set 4 and 23 samples
included in Set 5. Retrospective cohorts of samples were
collected from patients with lung cancer undergoing
treatment with nivolumab. Based on RECIST V.1.1
criteria,24 11 of the 28 patients (39.3%) in Set 4 and 9 of
the 23 (39.1%) in Set 5 benefited from nivolumab-based
treatment (partial response and stable disease) (online
supplemental table S2).
First, we captured concordance between IHC-
based
measurements and RPPA data for a subgroup of these 28
patients in Set 4 (figure 4A). IHC data were collected by
the enrolling institutions using clone 22C3 (n=15) and
scored by a certified pathologist (MM, GB for samples
collected in Italy). Samples scored as negative by IHC
presented a sevenfold dynamic range in PD-L1 expression
by RPPA. Of interest, only one of the seven responders
was correctly identified by IHC using the 22C3 clone
(figure 4A,D). In addition, three of the responders
(60%) classified as negative by IHC presented with PD-L1
expression levels by RPPA comparable to IHC positive
individuals. These false negative results may be associated with tissue fixation, antibody dilution, and epitope
retrieval methods required for the IHC analysis.39 Thus,
while the level of concordance between the two techniques was relatively low, the RPPA correctly defined a
subgroup of responders (n=3) that were missed by IHC.
A few IHC representative images of responders and non-
responders are shown in figure 4D along with matched
PD-L1 measurements by RPPA.
We then examined PD-L1 expression in Set 4 using
the 28–8 clone provided by Abcam, which was developed
against the same peptide sequence used for the antibody included in the 28–8 PharmDX assay. This assay has
been approved by the FDA as a complementary test for
patients stratification to nivolumab. As expected, PD-L1
expression was highly heterogeneous across responders
8

and non-
responders (online supplemental figure
S9). However, a subgroup of non-
responders (53%)
presented with PD-L1 levels significantly lower than any
of the patients that benefited from treatment (p<0.01)
(figure 5). Among the nine non-
responders with low
PD-L1 expression by RPPA, equal to the bottom tertial
of the population, eight out of nine (88.8%) were also
correctly identified by atezolizumab and seven out of
nine (77.8%) by the FDA-approved clone SP142 and the
research-based clone E1L3N (figure 5).
Similar trends were also observed for Set 5 where
PD-L1 expression was captured by IHC and RPPA using
the E1L3N clone (figure 4B). Overall, samples with high
PD-L1 levels by IHC presented with high relative expression by RPPA, suggesting an overall good level of concordance especially in tumors with high expression of PD-L1.
However, a number of IHC negative samples (n=6) had
PD-L1 levels by RPPA that mimic the IHC positive specimens (figure 4B). Of interest, within IHC negative specimens, the RPPA-based PD-L1 measurements identified
a subgroup of patients (n=5 red arrow in figure 4B) that
benefited from nivolumab. As shown for Set 4, six of the
seven samples (85.7%) belonging to the bottom tertial
of the population did not benefit from treatment with
nivolumab. The data presented in Set 4E and 5 suggest that
lack of response to nivolumab in patients with low PD-L1
expressing tumors, may be more correctly predicted by
RPPA than by standard IHC. Thus, RPPA-based measurements may be a valuable tool for identifying subgroups of
specimens that may be misclassified by standard IHC as
low PD-L1 expressing tumors (figure 6). Taken together,
our data indicate that RPPA-based measurements may
offer new opportunities for developing diagnostic tools
for stratifying patients to immunotherapy.
DISCUSSION
Undoubtedly, immune-checkpoint inhibitors are a highly
beneficial class of compounds for patients with cancer.1
However, the development of accurate molecular assays
and the identification of biomarkers to effectively
stratify patients to treatment remains an unmet need
in oncology.40 41 FDA approved IHC-based companion/
complementary assays for the detection of PD-L1 have
shown broad sensitivity and specificity in NSCLC (36%–
84% and 48%–78%, respectively).42 While replacing IHC
scoring as a routine clinical practice remains unfeasible,
devising novel orthogonal tests, like tumor mutational
burden testing, that can be used alongside with standard
IHC assays, remains an important aspect for improving the
diagnostic process and response prediction to antibody-
based immunotherapies. For example, the LCM/RPPA
workflow described, which has now graduated to a
commercially available Clinical Laboratory Improvement
Amendments/Laboratory Developed Test (CLIA/LDT)
assay, may be used alongside with conventional IHC testing
to allocate patients to treatment (figure 6). The standardized format of the assay is designed to capture molecular
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179
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and AKT in 3 of the 10 study Sets. As shown in online
supplemental figure S8A,B, concordance levels between
antibodies targeting activation sites of the S6 Ribosomal
Protein were >0.90. Similar values were also obtained for
the activated AKT regardless of tissue of origin, collection methods, and dissection process (range rs=0.70 to
0.96). Likewise, therapeutic antibodies targeting the
PD-1 receptor, namely pembrolizumab and nivolumab,
showed correlation coefficients ranging from 0.83 to 0.93
(online supplemental figure S8C). Taken together, these
data suggest a lower level of concordance across different
anti-PD-L1 antibody clones than what has been reported
for IHC-based quantification (rs <0.50 for 61% of pairwise
comparisons).

Open access

data from individual or batched samples and the staining
procedure mimics many of the steps used for IHC-based
analyses (figure 7). Thus, the assay can be performed on
a daily basis and capture expression of target analytes
for batched or individual samples. As we have previously
demonstrated, the entire LCM/RPPA workflow described
can generate results for small panels of biomarkers in a
short turnaround time (3 business days), with a minimal
impact on treatment initiation.18 Given the potential of
the RPPA to provide expanded dynamic range of PD-L1
expression, if validated on a larger study set, this assay
may help identify, among patients whose tumors have
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

low or negative PD-L1 expression by IHC, those that are
destined to benefit from anti-PD-L1/PD-1 treatment.
From a technical perspective, as a high throughput and
multiplex assay able to generate continuous data, the
RPPA represents a unique and complementary tool to
standard IHC (figure 6). Because denatured cell/tissue
lysates are directly immobilized onto nitrocellulose slides,
the RPPA allows for the quantification of membrane,
cytosolic, and nuclear proteins without requiring tissue
permeabilization or antigen retrieval, two steps that are
crucial and have a strong impact on IHC-based measurements.39 43 44 In addition, the fluorescence-based detection
9
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Figure 4 RPPA and matched IHC-based PD-L1 expression comparison in tissues collected from nivolumab treatment
patients with Non-Small Cell Lung Cancer (NSCLC). Ranking plots capturing matched RPPA and IHC PD-L1 expression data
for a subset of samples collected from responders (orange) and non-responders (blue) for Set 4 and Set 5 (A and B). PD-L1
expression was measured using the anti-PD-L1 clones 22C3 and E1L3N, respectively. RPPA continuous values are displayed
on the x-axis and asterisks indicate IHC positive samples. Red arrows indicate IHC negative samples that presented with
relatively high expression level of PD-L1 by RPPA and responded to treatment. Ranking plots for Sets 4 and 5 (B and C) indicate
that samples within the bottom tertial of the population (red box) were mostly collected from patients that did not benefit from
treatment. IHC images of selected tissue samples collected from non-responders (Samples 1–3) and responders (Samples
4–5) to nivolumab (20× magnification). Of note, although defined as positive by IHC, sample 1 intensity staining was scored as
1 in 10% of cells. IHC were scored by a certified pathologist (GB and MM for samples collected at the University of Perugia).
Corresponding RPPA values are highlighted in the scatter plot (bottom right corner). The RPPA measurements identified
two specimens from non-responders (1 and 3) with relatively low PD-L1 expression compared to IHC positive tumors; both
specimens derived from responders (4 and 5) had high PD-L1 levels by RPPA including a sample that was scored as negative
by IHC (5). These data only partially matched the IHC scoring (D). IHC, immunohistochemistry; PD-L1, programmed cell death
ligand 1; RPPA, reverse phase protein microarray.
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system used for the RPPA has important advantages over
the chromogenic substrates routinely used in IHC-based
analyses. For example, the biophysical properties and
absorbance of the 3,3’-Diaminobenzidine affect signal to
noise ratio and the analytical dynamic range of detection
of the assay.11 14 As such, output data for FDA approved
companion/complementary tests remain qualitative in
nature and fail to capture the linear relationship between
biomarker expression levels and outcome.11 Quantitative
fluorescence-based assays have previously been tested to
explore range of expression and prediction of response

to targeted agents and have shown superior predictive
value compared with standardized IHC, especially for
biospecimens within the lower range of detection of the
assay.13–16 As shown by our data, the use of a fluorescence-
based detection system allows capture of broad dynamic
ranges of protein expression on a continuous scale even
in samples that are defined as negative by conventional
IHC testing.
Of interest, our data also suggest a more heterogeneous and often a lower degree of correlation across
anti-
PD-
L1 antibody clones compared with IHC-
based

Figure 6 Workflow illustrating the potential role of the RPPA in allocating patients to anti-PD-1/PD-L1 treatment. PD-L1
expression on microdissected tumor cells by RPPA can be used alongside tumor mutational border to identify patients with
low PD-L1 expression levels by IHC that may benefit from anti-PD-1/PD-L1 treatment. IHC, immunohistochemistry; PD-L1,
programmed cell death ligand 1; RPPA, reverse phase protein microarray.
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Figure 5 RPPA-based PD-L1 expression captured with six anti-PD-L1 antibody clones in patients with lung cancer treated
with nivolumab. Normalized relative RPPA intensity units are displayed to capture PD-L1 distribution across the 28 samples
collected from nivolumab treated patients based on patients’ outcome. Emphasis is placed on the bottom tertial of the
population (n=9). PD-L1, programmed cell death ligand 1; RPPA, reverse phase protein microarray.
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comparisons,7 9 10 38 45–49 although levels of concordance
differ significantly across studies.38 50 51 Methodological
and biological reasons may explain the differences in
performance across antibody clones. For example, low
levels of concordance between the 22C3 anti-PD-L1 antibody and the remaining clones may be due to unspecific
binding of the 22C3 antibody to cytosolic proteins as
shown in online supplemental figure S10. In addition,
location of the target epitopes may explain the divergent
measurements captured by RPPA. Indeed, the SP142,
CAL10 and E1L3N clones bind to the intracellular
portion of PD-L1.37 The recognition of cytosolic portions
of the ligand by these three antibodies may explain the
relatively higher level of concordance detected by RPPA
between the SP142, CAL10, and E1L3N antibodies. The
22C3 and 28–8 clones, on the other hand, recognize
distinct fragments of the extracellular portion of PD-L1,
with the 22C3 binding to non-linear epitopes and the
28–8 clone recognizing discontinuous segments of the
extracellular domains.52
Similarly, quantitative immunofluorescence-
based
HER2 measurements in breast cancer specimens using
antibodies targeting intracellular and extracellular
domains of the receptor have shown discordant levels of
HER2 expression. These differences are lost in IHC-based
Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

analyses. However, only HER2 quantification captured by
the antibody targeting the extracellular portion of the
receptor was associated with response to trastuzumab.14
Cleavage of the extracellular portion of the HER2 and
expression of truncated forms of the receptor were identified as potential biological mechanisms responsible for
these discrepancies. Likewise, the extracellular domain
of PD-L1 is a known target of extracellular matrix metalloproteases.2 53 54 This may explain the lower correlation
levels detected by RPPA across antibody clones and the
ability of the 28–8 clone to identify a subgroup of tumors
on the lower end of the detection range that did not
benefit from treatment (figure 4).
Indeed, when association between PD-
L1 levels and
response to treatment with nivolumab was analyzed, the
RPPA continuous measurements identified a subgroup
of non-responders (53%), equal to the bottom tertial of
the population distribution, with PD-L1 levels lower than
any of the patients that experienced partial response
or stable disease. Retrospective biomarker analyses of
phase III clinical trials assessing the predictive value of
PD-L1 expression by IHC in second-line treatment with
nivolumab have reported response rates of approximately 20% for patients with PD-L1 positive lung cancer.4
In the pretreated cohort of patients included in this
11
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Figure 7 Workflow illustrating the use of LCM coupled with RPPA in the diagnostic setting. First, tumor content in surgical
samples and core needle biopsies is assessed by a certified pathologist and malignant cells are isolated from the surrounding
microenvironment using LCM (A). Isolated cells are then lysed and immobilized onto nitrocellulose coated glass slides using
a robotic system. Reference standard spanning the dynamic range of the analyte of interest and a set of internal controls are
printed alongside with the clinical samples. Arrays are stained using an antibody-based detection system and absolute intensity
values are generated for each sample and control (B). Intensity values of individual samples and controls are then interpolated
from the reference standard and compared with a reference population matching the clinical characteristics of the samples (C).
Expression levels of the measured analysis in the control samples are used as QA/QC steps to track precision and accuracy
of the assay (C). Final results and QA/QC data are reviewed by a certified pathologist or a laboratory director and included in
a final report (D). LCM, laser capture microdissection; PD-1, programmed cell death protein 1; PD-L1, programmed cell death
ligand 1; RPPA, reverse phase protein microarray.
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Terminology (CPT) codes (ie, 88380 and 88381). Thus,
integration of these enrichment methods in clinical practice may increase in the near future. Lastly, the presence
of preanalytical variables represent a potential bias of this
work. However, trends were highly consistent across data
sets. For example, correlation between antibodies used in
FDA-cleared assays showed overall low levels of concordance in all data sets with all but two presenting with rs
of less than 0.60 when correlations between the SP142
and 28–8 clones were analyzed. Similar values were also
captured for the correlations between the 28–8 and the
22C3 clones (rs<0.60 in all but one Set). On the contrary,
we detected higher levels of concordance across the
board with the remaining clones. For example, correlations between CAL10 and SP142, CAL10 and E1L3N, or
E1L3N and SP142 had rs greater than 0.7 in 9 of the 10
(90%) study Sets. This high level of concordance across
data sets provides an analytical validation of our observations and indicates that most likely preanalytical variables
are not driving our observations.
Taken together, our data indicate that continuous RPPA-
based measurements capture a broad dynamic range of
PD-L1 expression in human specimens. Although this
data needs to be validated in larger and independent
cohorts of samples, using both diagnostic and therapeutic
anti-
PD-
L1 antibodies, this high throughput immunoassay can potentially identify, especially on the lower
end of the PD-L1 expression distribution, a subgroup of
tumors in which low expression of the ligand equates to
lack of response to anti-PD-1 agents. As previously shown,
RPPA standardized measurements can easily be generated
from laser captured microdissected clinical trial specimens, including small core needle biopsies, and can be
reported to treating physicians within 3–10 business days
from sample collection.18 19 33 Thus, this platform may
open novel opportunities for identifying patients that
may benefit from treatment with anti-PD-1/PD-L1 agents
as well as other immune-checkpoints inhibitors. As such,
the predictive value of RPPA-based PD-L1 measurements
and of the different antibody clones should be tested in
future retrospective and prospective investigations to validate its role as a companion test for allocating patients to
treatment.
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analysis, benefit from nivolumab was observed in 11 of
the 19 tumors (~60%) with PD-L1 levels greater than
the bottom tertial of the population. While IHC scoring
with the 28–8 clone is not currently required to allocate
patients to treatment with nivolumab, and any level of
PD-L1 expression is considered a potential indicator of
response, identifying predictive markers of response to
nivolumab-based treatment still remains an open challenge in immuno-oncology. Even if very preliminary, by
identifying a subgroup of tumors with low PD-L1 expression that do not respond to treatment, our data indicate
that PD-L1 expression captured by RPPA with the FDA-
approved 22–8 clone may provide valuable insights to the
diagnostic process. However, because the cut-off value
used in this work was arbitrary, our findings need to be
validated on a larger cohort of samples after the assay has
been standardized.33
Although outside of the scope of this work, the standardization of this assay can easily be developed as previously described (figure 7).21 33 55 56 First, PD-L1 expression
levels measured by RPPA need to be collected from a large
cohort of patients with NSCLC treated with a PD-L1/
PD-
1 inhibitor (training cohort) along with reference
standards. This process is a key step for assessing whether
the dynamic range of the population is contained within
the linear range of the reference standards and for identifying a cut-
off value able to discriminate responders
from non-responders (online supplemental figure S11).
Controls with values above and below the cut-
off are
then identified and used to assess the performance of
the platform over time. A second independent cohort
of samples (validation cohort) is then used to assess the
ability of the test to predict response to treatment. For
each sample in the validation cohort, absolute RPPA
values are transformed into relative intensity values of
the reference standard and compared with the reference
population to predict response to treatment (figure 7). If
the assay shows sensitivity, specificity, and positive/negative predictive values that are equal or superior to other
FDA-approved tests, the assay can then be used to analyze
individual or batched samples (figure 7).
While our preliminary data are encouraging, a few
limitations of the study need to be addressed. First, the
clinical relevance of our observations was assessed in two
small cohorts of samples. Thus, to fully understand the
role of the RPPA in predicting response to treatment
with anti-PD-1/PD-L1 inhibitors, the assay needs to be
standardized and tested against larger and independent sample sets as described above (figure 7). Second,
although we have previously demonstrated that the LCM/
RPPA workflow can be used to analyze clinical trials specimens,20 33 55 56 the routine integration of the LCM into clinical and molecular pathology may be challenging from a
technical perspective as it adds time and effort to the diagnostic process. However, LCM and microdissection techniques in general are a growing component of a number
of clinical Next Generation Sequencing (NGS) workflows
and have recently been assigned Current Procedural

Open access
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la
Cura dei Tumori (IRST) IRCCS, Meldola, Italy
11
Division of Medical Oncology, S. Maria della Misericordia Hospital, Perugia, Italy
Twitter Martina Mandarano @MartinaMandara4
Contributors Conceptualiastion/study design: EB, EFP, MP. Sample and data
collection: LC, VL, GGa, GGi, NJS, MB, AR, FO, RR, JdB, AS, BD, MA-K, NM.
Experimental procedures: EB, GB, GGa, CR, MM, JW, RIG, LL, MIS, AZ, GI, PD, MP.
Data analysis and interpretation: EB, GB, MM, AS, EFP, MP. Manuscript preparation
and final approval: All authors.
Funding This work was supported by the Side Out Fondation, the Istituto Superiore
di Sanità (Rome, Italy), and by the College of Science, George Mason University.
The I-SPY work was conducted with support from Quantum Leap Healthcare
Collaborative, FNIH, NCI (Grant P01 CA210961), Safeway, an Albertsons Company,
William K. Bowes, Jr. Foundation, Breast Cancer Research Foundation, UCSF, GMU,
Gateway for Cancer Research (Grant G-16-900), the Biomarkers Consortium,
Salesforce, OpenClinica, Formedix, Natera, Hologic, TGen, Illumina, CCS Associates,
Berry Consultants, Breast Cancer Research – Atwater Trust, Stand up to Cancer,
California Breast Cancer Research Program, and Give Breast Cancer the Boot, IQVIA,
Genentech, Amgen, Pfizer, Merck, Seattle Genetics, Daiichi Sankyo, AstraZeneca,
Dynavax Technologies, Puma Biotechnology, AbbVie, Madrigal Pharmaceuticals
(formerly Synta Pharmaceuticals), Plexxikon, Regeneron, and Agendia.
Competing interests The authors are inventors on US Government and University
assigned patents and patent applications that cover aspects of the technologies
discussed such as the Reverse Phase Protein Microarrays. As inventors, they
are entitled to receive royalties as provided by US Law and George Mason
University policy. MP, JW, LL and EFP receive royalties from and are consultants of
TheraLink Technologies. EFP and LL are shareholders and consultants of TheraLink
Technologies. EFP is shareholder and consultant of Perthera.
Patient consent for publication Not applicable.
Ethics approval Sample collection and their use for molecular analysis were
approved by the enrolling institutions. Samples were collected under voluntary
consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.
Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any opinions or recommendations discussed are solely those
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and
responsibility arising from any reliance placed on the content. Where the content
includes any translated material, BMJ does not warrant the accuracy and reliability
of the translations (including but not limited to local regulations, clinical guidelines,
terminology, drug names and drug dosages), and is not responsible for any error
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0 /.
ORCID iDs
Elisa Baldelli http://orcid.org/0000-0002-6 288-4599
Mariaelena Pierobon http://orcid.org/0000-0003-2084-1029

REFERENCES

1 Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as
cancer therapeutics. J Hematol Oncol 2019;12:92.
2 Gong B, Kiyotani K, Sakata S, et al. Secreted PD-L1 variants mediate
resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J Exp Med 2019;216:982–1000.
3 Carretero-González A, Lora D, Ghanem I, et al. Analysis of response
rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid
tumors: a meta-analysis of randomized clinical trials. Oncotarget
2018;9:8706–15.
4 Teixidó C, Vilariño N, Reyes R, et al. PD-L1 expression
testing in non-small cell lung cancer. Ther Adv Med Oncol
2018;10:1758835918763493.

Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

5 Havel JJ, Chowell D, Chan TA. The evolving landscape of
biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer
2019;19:133–50.
6 Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor
mutation burden as an immunotherapy biomarker: utility for the
oncology clinic. Ann Oncol 2019;30:44–56.
7 Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry
comparability study in real-life clinical samples: results of blueprint
phase 2 project. J Thorac Oncol 2018;13:1302–11.
8 Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a
systematic literature review of scoring algorithms and test-validation
metrics. Diagn Pathol 2018;13:12.
9 Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1
immunohistochemistry assays for lung cancer: results from phase
1 of the blueprint PD-L1 IHC assay comparison project. J Thorac
Oncol 2017;12:208–22.
10 Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional,
Pathologist-Based assessment of 4 immunohistochemistry assays
for PD-L1 expression in non-small cell lung cancer. JAMA Oncol
2017;3:1051–8.
11 Rimm DL. What brown cannot do for you. Nat Biotechnol
2006;24:914–6.
12 Liebler DC, Holzer TR, Haragan A, et al. Analysis of immune
checkpoint drug targets and tumor Proteotypes in non-small cell lung
cancer. Sci Rep 2020;10:9805.
13 Abubakar M, Figueroa J, Ali HR, et al. Combined quantitative
measures of ER, PR, HER2, and KI67 provide more prognostic
information than categorical combinations in luminal breast cancer.
Mod Pathol 2019;32:1244–56.
14 Carvajal-Hausdorf DE, Schalper KA, Pusztai L, et al. Measurement
of domain-specific HER2 (ErbB2) expression may classify benefit
from trastuzumab in breast cancer. J Natl Cancer Inst 2015;107
doi:10.1093/jnci/djv136
15 Yardley DA, Kaufman PA, Huang W, et al. Quantitative measurement
of HER2 expression in breast cancers: comparison with ‘real-world’
routine HER2 testing in a multicenter Collaborative Biomarker Study
and correlation with overall survival. Breast Cancer Res 2015;17:41.
16 Wulfkuhle JD, Berg D, Wolff C, et al. Molecular analysis of HER2
signaling in human breast cancer by functional protein pathway
activation mapping. Clin Cancer Res 2012;18:6426–35.
17 Jensen K, Erickson J, Webster S. Evaluation of tissue processing
factors affecting HER2 IHC staining intensity in breast cancer cell
lines. Cancer Res 2012;72.
18 Pierobon M, Silvestri A, Spira A, et al. Pilot phase I/II personalized
therapy trial for metastatic colorectal cancer: evaluating the
feasibility of protein pathway activation mapping for stratifying
patients to therapy with imatinib and panitumumab. J Proteome Res
2014;13:2846–55.
19 Jameson GS, Petricoin EF, Sachdev J, et al. A pilot study utilizing
multi-omic molecular profiling to find potential targets and select
individualized treatments for patients with previously treated
metastatic breast cancer. Breast Cancer Res Treat 2014;147:579–88.
20 Arnedos M, Vicier C, Loi S, et al. Precision medicine for metastatic
breast cancer-limitations and solutions. Nat Rev Clin Oncol
2015;12:693–704.
21 Wulfkuhle JD, Yau C, Wolf DM, et al. Evaluation of the HER/PI3K/
AKT family signaling network as a predictive biomarker of pathologic
complete response for patients with breast cancer treated with
neratinib in the I-SPY 2 trial. JCO Precis Oncol 2018;2:1–20.
doi:10.1200/PO.18.00024
22 Baldelli E, Bellezza G, Haura EB, et al. Functional signaling pathway
analysis of lung adenocarcinomas identifies novel therapeutic targets
for KRAS mutant tumors. Oncotarget 2015;6:32368–79.
23 Zupa A, Improta G, Silvestri A, et al. A pilot characterization of human
lung NSCLC by protein pathway activation mapping. J Thorac Oncol
2012;7:1755–66.
24 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response
evaluation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer 2009;45:228–47.
25 Sereni MI, Baldelli E, Gambara G, et al. Kinase-driven metabolic
signalling as a predictor of response to carboplatin-paclitaxel
adjuvant treatment in advanced ovarian cancers. Br J Cancer
2017;117:494–502.
26 Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus
neoadjuvant chemotherapy on pathologic complete response
in women with early-stage breast cancer: an analysis of the
ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol
2020;6:676–84.
27 Abu-Khalaf MM, Hatzis C, Hodge KA, et al. Multiomic advanced
diagnostics for CDK 4/6 drug target activation mapping of HR+/
HER2- metastatic breast cancer [abstract].

13

J Immunother Cancer: first published as 10.1136/jitc-2020-002179 on 7 October 2021. Downloaded from http://jitc.bmj.com/ on October 25, 2021 by guest. Protected by copyright.

10

Open access

14

43 Bogen SA, Vani K, Sompuram SR. Molecular mechanisms of antigen
retrieval: antigen retrieval reverses steric interference caused by
formalin-induced cross-links. Biotech Histochem 2009;84:207–15.
44 Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get
along: revisiting the technical aspects of immunohistochemistry-the
red, brown, and blue technique. Vet Pathol 2014;51:42–87.
45 Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization
study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol
2018;29:953–8.
46 Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between
programmed cell death ligand-1 diagnostic assays across multiple
protein expression cutoffs in non-small cell lung cancer. Clin Cancer
Res 2017;23:3585–91.
47 Marchetti A, Barberis M, Franco R, et al. Multicenter comparison
of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test
PD-L1 expression for NSCLC patients to be treated with immune
checkpoint inhibitors. J Thorac Oncol 2017;12:1654–63.
48 McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of
the heterogeneity of PD-L1 expression in non-small-cell lung cancer.
JAMA Oncol 2016;2:46–54.
49 Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of
antibodies to programmed cell death 1 ligand 1. JAMA Oncol
2017;3:256–9.
50 Pinato DJ, Mauri FA, Spina P, et al. Clinical implications of
heterogeneity in PD-L1 immunohistochemical detection in
hepatocellular carcinoma: the Blueprint-HCC study. Br J Cancer
2019;120:1033–6.
51 Brunnström H, Johansson A, Westbom-Fremer S, et al. PD-L1
immunohistochemistry in clinical diagnostics of lung cancer: inter-
pathologist variability is higher than assay variability. Mod Pathol
2017;30:1411–21.
52 Kintsler S, Cassataro MA, Drosch M, et al. Expression of
programmed death ligand (PD-L1) in different tumors. Comparison of
several current available antibody clones and antibody profiling. Ann
Diagn Pathol 2019;41:24–37.
53 Orme JJ, Jazieh KA, Xie T, et al. ADAM10 and ADAM17 cleave
PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology
2020;9:1744980.
54 Romero Y, Wise R, Zolkiewska A. Proteolytic processing of PD-L1 by
ADAM proteases in breast cancer cells. Cancer Immunol Immunother
2020;69:43–55.
55 Wolf DM, Yau C, Wulfkuhle J, et al. Mechanism of action biomarkers
predicting response to AKT inhibition in the I-SPY 2 breast cancer
trial. NPJ Breast Cancer 2020;6:48.
56 Pierobon M, Robert NJ, Northfelt DW, et al. Multi-omic profiling of
metastatic lesions to guide treatment selection: the side out 2 trial
experience. JCO 2018;36:1077.

Baldelli E, et al. J Immunother Cancer 2021;9:e002179. doi:10.1136/jitc-2020-002179

J Immunother Cancer: first published as 10.1136/jitc-2020-002179 on 7 October 2021. Downloaded from http://jitc.bmj.com/ on October 25, 2021 by guest. Protected by copyright.

28 Improta G, Zupa A, Fillmore H, et al. Protein pathway activation
mapping of brain metastasis from lung and breast cancers
reveals organ type specific drug target activation. J Proteome Res
2011;10:3089–97.
29 Signore M, Manganelli V, Hodge A. Antibody validation by Western
blotting. Methods Mol Biol 2017;1606:51–70.
30 Baldelli E, Haura EB, Crinò L, et al. Impact of upfront cellular
enrichment by laser capture microdissection on protein and
phosphoprotein drug target signaling activation measurements
in human lung cancer: implications for personalized medicine.
Proteomics Clin Appl 2015;9:928–37.
31 Espina V, Wulfkuhle JD, Calvert VS, et al. Laser-capture
microdissection. Nat Protoc 2006;1:586–603.
32 Baldelli E, Calvert V, Hodge A, et al. Reverse phase protein
microarrays. Methods Mol Biol 2017;1606:149–69.
33 Pierobon M, Ramos C, Wong S, et al. Enrichment of PI3K-AKT-mTOR
pathway activation in hepatic metastases from breast cancer. Clin
Cancer Res 2017;23:4919–28.
34 Pin E, Federici G, Petricoin EF. Preparation and use of reverse protein
microarrays. Curr Protoc Protein Sci 2014;75:27.7.1–9.
35 Mandarano M, Bellezza G, Belladonna ML, et al. Assessment of
TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an
immunohistochemical study with clinicopathological and prognostic
implications. Virchows Arch 2019;474:159–68.
36 Parra ER, Villalobos P, Mino B, et al. Comparison of different
antibody clones for immunohistochemistry detection of programmed
cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl
Immunohistochem Mol Morphol 2018;26:83–93.
37 Lawson NL, Dix CI, Scorer PW, et al. Mapping the binding sites of
antibodies utilized in programmed cell death ligand-1 predictive
immunohistochemical assays for use with immuno-oncology
therapies. Mod Pathol 2020;33:518–30.
38 Atsaves V, Tsesmetzis N, Chioureas D, et al. PD-L1 is commonly
expressed and transcriptionally regulated by STAT3 and MYC in ALK-
negative anaplastic large-cell lymphoma. Leukemia 2017;31:1633–7.
39 Gown AM. Diagnostic immunohistochemistry: what can go wrong
and how to prevent it. Arch Pathol Lab Med 2016;140:893–8.
40 Nixon AB, Schalper KA, Jacobs I, et al. Peripheral immune-based
biomarkers in cancer immunotherapy: can we realize their predictive
potential? J Immunother Cancer 2019;7:325.
41 Pin E, Stratton S, Belluco C, et al. A pilot study exploring the
molecular architecture of the tumor microenvironment in human
prostate cancer using laser capture microdissection and reverse
phase protein microarray. Mol Oncol 2016;10:1585–94.
42 Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry
assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res
2017;5:12.

